Medpace (MEDP) Stock Price, News & Analysis

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month target prices for Medpace's stock. Their MEDP share price targets range from $273.00 to $452.00. On average, they expect the company's share price to reach $382.00 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.

Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP shares have increased by 22.1% and is now trading at $374.32.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our MEDP earnings forecast.

Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings data on Monday, February, 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.24. The firm had revenue of $498.40 million for the quarter, compared to analyst estimates of $498.72 million. Medpace had a net margin of 15.00% and a trailing twelve-month return on equity of 63.98%. Medpace's revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.12 EPS.

ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Argent Mid Cap ETF (AMID), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM) and Invesco S&P MidCap 400 Pure Growth ETF (RFG).

Medpace updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share (EPS) guidance of 10.180-10.870 for the period, compared to the consensus estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (3.15%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%) and Congress Wealth Management LLC DE (0.09%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.